Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Translocator Protein 18 kDa (TSPO) Expression in Multiple Sclerosis Patients.
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Deleterious versus protective autoimmunity in multiple sclerosis.
Employment as a health promotion intervention for persons with multiple sclerosis.
Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum.
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.
Exploring the potential of public proteomics data.
Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports.
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Autoimmune disease prevalence in a multiple sclerosis cohort in Argentina.
Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients.
Epithelial v-like antigen mediates efficacy of anti-alpha4 integrin treatment in a mouse model of multiple sclerosis.
Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23.
The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.
Cognitive impairment is correlated with reduced quality of life in patients with clinically isolated syndrome.
Current and emerging therapies in multiple sclerosis: a systematic review.
Neurosarcoidosis as an MS Mimic: The trials and tribulations of making a diagnosis.
Peripheral blood mononuclear cell membrane fluidity and disease outcome in patients with multiple sclerosis.
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study.
MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing.
Automatic multiple sclerosis lesion detection in brain MRI by FLAIR thresholding.
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.
Pages
« first
‹ previous
…
272
273
274
275
276
277
278
279
280
…
next ›
last »